Core Viewpoint - AbbVie Inc. is expected to report significant growth in Q4 2025 earnings, with analysts projecting an EPS increase to $3.36 and quarterly revenue reaching $16.39 billion, indicating a positive trend in the company's financial performance [1]. Financial Performance - AbbVie is set to report Q4 2025 earnings on January 30, with an expected EPS of $3.36, up from $2.16 in the prior-year period [1]. - Quarterly revenue is anticipated to be $16.39 billion, an increase from $15.10 billion a year earlier [1]. - For Q3 2025, AbbVie reported revenues of $15.78 billion, surpassing the consensus estimate of $15.59 billion, with an adjusted EPS of $1.86, above the consensus of $1.79 [5]. Historical Investment Performance - AbbVie stock was approximately $60.29 per share 10 years ago, and an investment of $10,000 would have grown to $38,509 based on stock price appreciation alone [2]. - Over the past decade, AbbVie paid about $48.95 in dividends per share, resulting in $8,119 from dividends alone, leading to a total investment value of $46,628, representing a total return of 366.28% [3]. Dividend Information - AbbVie currently has a dividend yield of 3.02% and has consistently raised its dividend for the last 12 years [6]. - The company raised its full-year 2025 adjusted EPS guidance to a range of $10.61 to $10.65, above the previous range and consensus estimate [6]. Analyst Ratings and Price Target - AbbVie has a consensus rating of "Overweight" with a price target of $232.65, indicating a potential upside of approximately 0.1% from the current stock price [5].